References
- Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
- Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264–1277.
- Jiang A, Reece D, Chang H. Genomic stratification of multiple myeloma treated with novel agents. Leuk Lymphoma 2012;53:202–207.
- Reece DE, Leitch HA, Atkins H, . Treatment of relapsed and refractory myeloma. Leuk Lymphoma 2008;49:1470–1485.
- Kumar SK, Lee JH, Lahuerta JJ, . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2011;26:149–157.
- Bird JM, Owen RG, D’Sa S, . Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154:32–75.
- Lazzarino M, Corso A, Barbarano L, . DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835–839.
- Srikanth M, Davies FE, Wu P, . Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432–436.
- Lee CK, Barlogie B, Munshi N, . DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732–2739.
- Grey-Davies E, Bosworth JL, Boyd KD, . Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012;156:552–555; author reply 555.